Price Alert

Mineralys Therapeutics In... (MLYS)

NASDAQ: MLYS · Real-Time Price · USD

38.06

-2.40 (-5.93%)

At close: Oct 03, 2025, 3:59 PM

38.50

1.16%

After-hours: Oct 03, 2025, 07:30 PM EDT

-5.93% (1D)

Bid	36.27
Market Cap	2.52B
Revenue (ttm)	34K
Net Income (ttm)	-190.77M
EPS (ttm)	-3.74
PE Ratio (ttm)	-10.18
Forward PE	-15.27
Analyst	Buy
Dividends	n/a

Ask	40.55
Volume	949,908
Avg. Volume (20D)	1,531,190
Open	40.91
Previous Close	40.46
Day's Range	38.03 - 40.91
52-Week Range	8.24 - 41.09
Beta	0.40
Ex-Dividend Date	n/a

About MLYS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MLYS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MLYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+2.45%

Mineralys Therapeutics shares are trading higher a... Unlock content with Pro Subscription

4 months ago

-1.44%

MLYS stock has given up its prior gain. Mineralys Therapeutics shares were trading higher after the company announced it presented Launch-HTN data at ESH 2025 and demonstrated its efficacy for over 1,000 patients.

News

4 days ago · seekingalpha.com

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions

Mineralys Therapeutics, Inc. advances lorundrostat, its lead aldosterone inhibitor, for uncontrolled and resistant hypertension with pivotal Phase 3 successes. Mineralys achieved positive Phase 2 resu...

6 days ago · zacks.com

Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy?

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 week ago · fool.com

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.

2 weeks ago · seekingalpha.com

3 Potential Biotech Acquisition Targets

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...

2 weeks ago · fool.com

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps

Whether it's withering jobs data, renewed signs of inflation or sluggish consumer spending, there's been no shortage of concerning economic news over the past month. And yet, this gloomy backdrop has ...

3 weeks ago · zacks.com

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · benzinga.com

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday.

1 month ago · zacks.com

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is qu...

1 month ago · seekingalpha.com

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jo...

2 months ago · zacks.com

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Load More News